Peptide Degradation: Why Peptides Break Down & Prevention

The human body is equipped with an extensive arsenal of proteases — enzymes whose sole purpose is to break peptide bonds. This presents a fundamental challenge for therapeutic peptides.

Key protease families: - Serine proteases: Trypsin, chymotrypsin, elastase — abundant in the GI tract and blood - Metalloproteinases: NEP (neprilysin), ACE — found in vascular endothelium and various tissues - Cysteine proteases: Cathepsins — primarily intracellular, involved in lysosomal degradation - Aspartyl proteases: Pepsin — active in the acidic stomach environment

DPP-4 (Dipeptidyl Peptidase-4): This enzyme deserves special mention because it rapidly degrades several therapeutically important peptides: - Cleaves GLP-1 (half-life ~2 minutes) and GIP - This is why native GLP-1 is impractical as a drug - DPP-4 inhibitors (gliptins) are an entire drug class designed to prevent this degradation - Semaglutide's design specifically addresses DPP-4 susceptibility

The result: Most unmodified peptides have plasma half-lives measured in minutes. Natural GLP-1 lasts about 2 minutes, natural GHRH about 7 minutes, and natural GnRH about 2–4 minutes. This rapid degradation is why peptide engineering is essential for therapeutic applications.

Beyond enzymatic degradation, peptides face chemical degradation from environmental conditions:

pH-dependent degradation: - Acidic conditions (pH < 3): Accelerate hydrolysis of acid-labile bonds, particularly Asp-Pro sequences - Alkaline conditions (pH > 8): Promote deamidation of asparagine and glutamine residues, racemisation of amino acids - Optimal stability: Most peptides are most stable between pH 4–6 - The stomach's pH of 1.5–3.5 is particularly destructive — this is why oral peptide delivery is so challenging

Temperature effects: - Higher temperatures accelerate all chemical degradation reactions (Arrhenius principle) - Every 10°C increase roughly doubles the rate of degradation - Aggregation: heat causes peptides to unfold and clump together, forming inactive or immunogenic aggregates - Freeze-thaw cycles can also damage peptides through ice crystal formation and concentration effects

Oxidation: - Methionine and cysteine residues are particularly vulnerable to oxidation - Exposure to light, air, or metal ions accelerates oxidative damage - Oxidised peptides may lose biological activity or gain immunogenic properties

Practical implications: These vulnerabilities explain why peptide storage conditions are critical — most reconstituted peptides require refrigeration at 2–8°C, protection from light, and use within defined timeframes.

Pharmaceutical scientists have developed numerous strategies to improve peptide stability and extend half-lives:

Amino acid substitutions: - Replacing L-amino acids with D-amino acids at protease cleavage sites - Substituting natural amino acids with non-natural analogues (e.g., alpha-aminoisobutyric acid/Aib) - Semaglutide uses an Aib substitution at position 8 to resist DPP-4 cleavage

Cyclisation: - Forming a ring structure reduces conformational flexibility and protease access - Melanotan II's cyclic structure gives it far greater stability than linear alpha-MSH - Cyclosporine is a classic example of a cyclic peptide with oral bioavailability

PEGylation: - Attaching polyethylene glycol (PEG) chains to the peptide - Increases molecular size (reducing renal clearance) - Shields the peptide from protease access - Can reduce immunogenicity

Lipidation (fatty acid conjugation): - Semaglutide's key innovation: a C18 fatty acid chain enables albumin binding - Albumin-bound peptide is protected from proteases and renal filtration - Extends semaglutide's half-life to ~7 days (vs 2 minutes for native GLP-1)

Drug Affinity Complex (DAC): - Used in CJC-1295-DAC to enable albumin binding - Similar principle to lipidation but using a reactive chemical linker

Beyond molecular engineering, formulation science plays a crucial role in peptide stability:

Lyophilisation (freeze-drying): - Removes water to create a stable powder form - Most research peptides are supplied as lyophilised powders - Can remain stable for months or years when stored properly - Requires reconstitution with bacteriostatic water or saline before use

Excipients and stabilisers: - Mannitol and trehalose act as cryoprotectants during lyophilisation - Buffers maintain optimal pH during storage - Surfactants (e.g., polysorbate 80) prevent surface adsorption and aggregation - Antioxidants protect against oxidative degradation

Oral delivery approaches: - Enteric coatings protect peptides through the stomach - Permeation enhancers (e.g., SNAC in oral semaglutide/Rybelsus) transiently increase gut absorption - Nanoparticle encapsulation is being researched for improved oral bioavailability - Despite advances, oral bioavailability remains low (~1% for oral semaglutide)

Alternative delivery routes: - Intranasal (selank, oxytocin) — avoids GI degradation, potential CNS access - Transdermal patches — sustained release, avoids first-pass metabolism - Depot injections — slow-release formulations for extended duration

Understanding degradation mechanisms has direct practical implications:

Storage matters enormously: - Lyophilised (powder) peptides: store frozen or refrigerated, away from light - Reconstituted peptides: refrigerate at 2–8°C, use within the manufacturer's specified timeframe - Never freeze reconstituted peptides unless specifically instructed - Bacteriostatic water (containing 0.9% benzyl alcohol) helps prevent microbial contamination

Reconstitution technique: - Add bacteriostatic water gently to the vial wall — do not blast the powder directly - Swirl gently rather than shaking vigorously (agitation causes aggregation) - Allow the powder to dissolve completely before drawing doses

Quality indicators: - Clear, colourless solution after reconstitution is expected for most peptides - Cloudiness, particulates, or colour changes suggest degradation - Discard any vial showing these signs

Why this science matters for safety: Degraded peptides are not simply "weaker" — they can form aggregates that trigger immune responses, produce bioactive fragments with unintended activity, or contain oxidation products with unknown effects. Proper handling is not merely about potency; it is a safety consideration.

*This article is for educational purposes only. Always follow manufacturer guidelines for peptide storage and handling. Use peptides only under medical supervision.*